Andrew is the principal consultant of Next Gen Editing. Next Gen Editing is a consulting firm focused on unlocking the full potential of gene editing to create medicines that re-write DNA to cure disease, improve the quality of life, and allow us to live long, healthy, and fulfilling lives.

Previously, Andrew headed the Computational Biology and Genomics work at CRISPR Therapeutics, analyzing edited DNA sequencing data. He also organized cancer genomics data at Agios Pharmaceuticals, integrating it into metabolic pathways and drug targets. His contributions at the Broad Institute of MIT and Harvard included developing a system for detecting DNA variants and GATK, a toolkit for analyzing massive genomic data. He led projects such as detecting de novo mutations, identifying systematic errors in sequencing data, and optimizing sequencing protocols.

Before joining the Broad Institute, Andrew completed his Ph.D. at Columbia University in the Burkhard Rost Lab, using genetic algorithms to predict protein function. His undergraduate studies in Chemistry and Biochemistry at La Salle University involved extensive work with gene expression platforms at Rhone-Poulenc Rorer (now part of Sanofi Aventis) and Merck Research Labs, balancing laboratory research with computational data exploration and tool development.

In his free time, Andrew enjoys spending time flying airplanes.